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A B S T R A C T
Purpose
The systematic use of patient-reported outcome measures (PROMs) has been advocated as an
effective way to standardize cancer practice. Yet, the question of whether PROMs can lead to
actual improvements in the quality of patient care remains under debate. This review examined
whether inclusion of PROM in routine clinical practice is associated with improvements in patient
outcomes, processes of care, and health service outcomes during active anticancer treatment.
Methods
A systematic review of five electronic databases (Medline, EMBASE, CINAHL [Cumulative Index
to Nursing and Allied Health Literature], PsycINFO, and Psychology and Behavioral Sciences
Collection [PBSC]) was conducted from database inception to May 2012 to locate randomized and
nonrandomized controlled trials of patients receiving active anticancer treatment or supportive
care irrespective of type of cancer.
Results
Based on prespecified eligibility criteria, we included 26 articles that reported on 24 unique
controlled trials. Wide variability in the design and use of interventions delivered, outcomes
evaluated, and cancer- and modality-specific context was apparent. Health service outcomes were
only scarcely included as end points. Overall, the number of statistically significant findings were
limited and PROMs’ intervention effect sizes were predominantly small-to-moderate.
Conclusion
The routine use of PROMs increases the frequency of discussion of patient outcomes during
consultations. In some studies, PROMs are associated with improved symptom control, increased
supportive care measures, and patient satisfaction. Additional effort is required to ensure patient
adherence, as well as additional support to clinicians who will respond to patient concerns and
issues, with clear system guidelines in place to guide their responses. More research is required
to support PROM cost-benefit in terms of patient safety, clinician burden, and health
services usage.
J Clin Oncol 32:1480-1501. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Anticancer treatments have brought about definite
advances in patient survival rates.1 However, treat-
ment is associated with significant toxicity that is
potentially life-threatening,1 and can often result in
poor treatment adherence, impaired quality of life
(QoL), and mortality.2,3 Systematic monitoring is
crucial to detect problems, to address needs of pa-
tients, and toplancare.4Usingpatient-reportedout-
come measures (PROMs), “measurements of any
aspect of a patient’s health status that come directly
from the patient,”5 facilitates a systematic and com-
prehensive approach to patient assessment and
identifies problems that are often overlookedwithin
routine practice. Regularly collecting PROM data is
an effectiveway to standardize practice and improve
patientmanagement.4 Nevertheless, the question of
whether PROMs can improve the quality of patient
care, and whether this relates both to health profes-
sional engagement with them and to the system
guidelines inplace to guide response, remains under
debate. Given the costs associated with collecting
PROMs, evidence of their effect on patient out-
comes (POs), processes of care (PoCs), and/or
health service outcomes (HSOs) is needed.
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Previous reviewshave concluded someclinicallymeaningful, but
not always statistically significant, effects on the use of PROMs in
clinical practice.5-11 Only two of these reviews9,11 were specific to
cancer care and differed in terms of objectives, comprehensiveness,
and quality. Taking into consideration the lack of clarity around the
use of PROMs in cancer care, we conducted a comprehensive system-
atic review of all available controlled trials (CTs) to examine whether
routineuseofPROMsbyhealth careprofessionals (HPs) can improve
the quality of care patients receive during active anticancer treatment.
The value of PROM use was examined through detection of positive
effects on POs, PoCs, and HSOs, as suggested by statistical/clini-
cal changes.
METHODS
We searched five electronic databases (Medline, EMBASE, CINAHL [Cumu-
lative Index to Nursing and Allied Health Literature], PsycINFO, and PBSC)
from database inception to May 2012, using a systematic strategy that was
devised and refined through an iterative process (Appendix Table A1 [online-
only]). Additional articles were identified through previous topical
reviews.5-11 We also examined reference lists of the articles retained for any
studies thatmighthavebeenoverlooked.Wherenecessary,wecontacted study
authors to provide clarification on characteristics of the study samples in-
cluded.WefollowedthePreferredReporting Items forSystematicReviewsand
Meta-Analyses (PRISMA) guidelines where applicable.12
Study Selection Criteria
Trials were deemed eligible if they were primary or secondary reports of
CTs testing PROM interventions in which PROM-generated feedback was
made available to HPs or patients to improve quality of patient care; involved
adult patients ( 18 years old) with cancer, irrespective of disease stage, who
receivedany typeof active anticancer treatmentor supportive care, even if only
part of the sample received active treatment/care but percentages were re-
ported; were randomized CTs (RCTs) or non-RCTs; and were published in
the English language with readily available abstracts. Trials were excluded if
they evaluated PROMs as part of broader psychobehavioral interventions, in
which PROMs were only used to evaluate intervention effectiveness; investi-
gated the effects of a medicinal product; were conducted with survivors of
cancer who were not actively receiving anticancer treatment; tested the psy-
chometric properties of PROMs; or involved children with cancer, or survi-
vors of childhood cancers.
Study Selection and Data Extraction Procedures
Study selection involved two stages: an initial title and abstract screening
with eligibility evaluation performed by two screening groups that indepen-
dently screened the retrieved records against selection criteria, and retrieving
potentially eligible full-text articles, which were independently evaluated for
eligibility by five reviewers. Selection of the final sample of studies was dis-
cussed until a consensus was reached. Five reviewers extracted data using
forms thatwere specifically developed for this review, pilot tested the formson
three randomly selected studies, and refined the forms accordingly.
Risk of Bias and Methodologic Quality Evaluation
We used the Cochrane Collaboration Risk of Bias Tool13 to evaluate six
different domains of a CT: adequacy of sequence generation, concealment of
allocation, blinding, completeness of follow-up, freedom from reporting bias,
and other forms of bias. We evaluated each domain of bias as low risk, high
risk, or unclear. Three reviewers assessed five articles each, and a fourth re-
viewer cross-checked the evaluationsuntil a consensuswas reached.Reviewers
were not blinded to authors, institutions, or journals of publication.
Outcome Evaluation
Based on previous topical reviews,5-11 three major outcome categories
were formed:POs(ie,health status/well-being/functioning; symptomburden/
distress; health-relatedQoL; psychological distress), PoCs (ie, patient satisfac-
tion with treatment/care/consultation; patient behaviors/actions/adherence;
patient-HP communication; patient-HP concordance in assessments; HP en-
gagement in assessment), and HSOs (ie, patient safety; cost-effectiveness;
number of contacts with clinicians; patient resources/services use). We antic-
ipated that not all CTs would report on every outcome category or on every
outcome within a specific category.
Synthesis of Results and Determination of Effect Sizes
Individual outcomes were classified according to prespecified major
outcomecategories, andfindingswerenarratively synthesized.Prevalence (%)
of studies examining each individual outcome and major categories was ex-
amined and plotted. Because of variability in the patient populations, out-
comes assessed, outcome PROMs used, and reporting of results, we deemed a
meta-analysis was not feasible. However, where enough data were available,
effect sizes (ES; Cohen’s d) and 95% CIs were estimated based on mean
postintervention total scores of outcome measures or percentages of patients
reporting specificoutcomesbasedon specific formulas.14,15By convention,ES
where d  0.2 were considered small, d  0.5 were moderate, and d  0.8
were large.16
RESULTS
Search Results and Study Characteristics
Initial searches retrieved 4,997 references from electronic databases and
18 from previous published literature reviews.5-11 Twenty-six articles17-42 re-
porting on 24 unique CTs fulfilled eligibility criteria and were included in a
qualitative synthesis (Fig 1). All but four trials18,24,34,36 were RCTs, and 16
adopted a longitudinal study design (Table 1). Patient study samples varied
widely in size (median, 194 individuals; range, 48 to 1,134 individuals; for a
total of 6,279 individuals). HP samples varied similarly (median, 22 HPs;
range, four to 262HPs; total, n713), but theywere reported inonly 11 trials.
Nine CTs tested interventions designed specifically for patients with
breast,20,22,26,27 lung,20,29,30,33,34 or hematologic malignancies.32 Seventeen
CTs tested interventions delivered in the outpatient/ambulatory setting. Only
twoRCTs targeted patients with early-stage cancers.19,22 Thirty-seven percent
to 100% of patients were receiving active anticancer treatments during
studyparticipation, and these treatmentsweremost frequently chemother-
apy or radiotherapy.
In terms of intervention design, patients in the control group either
received usual care only19,21,28,34,36,41,42 or completed PROMs similar to that
of the experimental group, but feedback remained unavailable to
HP.17,18,24,26,30-33,37,40 Only one three-armRCT combined these two alterna-
tive conditions in the same design.35,38,39 In the more diverse CTs, PROMs
werecompletedathomeby theexperimental groupbutwerenot administered
to patients in the control group25,29; were completed by all participants, but
PROM summaries of the experimental groupwere only placed in themedical
records or sent toHPs20,23; or were completed by patients in the experimental
group only to direct further intervention based on distress expressed by a
subset of the group.20,22,27 In only five CTs did HPs follow specific guidelines
to guide response to PROM feedback.20,22,23,26,28
Twenty-nine PROMs were administered in the reviewed trials to help
deliver the interventions (Appendix Table A2). Eleven CTs relied on only one
intervention PROM, seven incorporated two PROMs, and six CTs used three
or more instruments.17,18,23,24,28,42 The most frequently used PROMwas the
EuropeanOrganisation for Research and Treatment of CancerQuality of Life
Questionnaire C30 (EORTC QLQ-C30; n 11). Other PROMs focused on
symptom prevalence and severity (n  11), supportive care needs (n  8),
QoL issues (n 5), or sources of distress (n 3). The PROMswere adminis-
tered on media including electronic platforms (n  11), paper-and-pencil
tools in clinic (n 12), take-home log books (n 3), andmailed assessments
and/or telephone interviews (n 7; Table 1).
Risk of Bias Within and Across Studies
Two RCTs were rated as low risk in five of the seven bias categories.26,29
Yet, bias in the design and/or reportingwas present in all of the included trials
(Table 2), regardless of whether patients were randomly assigned to the study
PROMs’ Value in Improving Cancer Care Outcomes
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condition. Only seven RCTs were rated as low risk on both the random-
assignment generation process and allocation-concealment bias.17,20,26-29,41
Conversely, all non-RCTswere consistently rated as high risk.With the excep-
tion of three RCTs,21,22,40 performance biaswas rated as high for all CTs given
that blinding on the HP level was not feasible. With the exception of seven
CTs,18,25,28-30,40,41 risk of detection bias was also deemed high or unclear. Ten
CTs were rated as high risk regarding attrition-related bias.18-20,24,27,33,35,38-42
Selective outcome reporting bias was predominantly unclear (n 18; 75%).
Additional sources of bias interfered with 15 CTs. Most frequently, authors
were unclear as to whetherHPswho received patient feedback actually used it
during consultations.
Outcomes Evaluation
POs and/or PoCs were reported as primary outcomes in 21 CTs
(87.5%) and 19CTs (79.2%), respectively; however, intervention effects on
HSOs were only scarcely investigated (Table 2 and Table 3).20,22,27,30,42
Eighteen CTs evaluated the effects of interventions in the long term ( 8
weeks), with follow-up assessments ranging in number from two to four or
more that were conducted for up to 12 months (but mainly 6 months)
after baseline assessment.
Patient Outcomes
Physical symptoms. Overall, positive effects with reduced symptomprev-
alenceor severitywere reported in sevenCTs (sixRCTs),mainly clinically and less
frequently statistically significant. ES ranged widely and were mainly small-to-
moderate in terms of intervention effects on physical symptom prevalence (d
0.01 to0.75),physical symptomseverity (d0.0 to0.44),psychological symptom
prevalence (d 0.07 to 0.15), psychological symptomseverity (d 0.01 to 0.30),
or psychological symptomdistress (d 0.09 to 0.42;AppendixTableA3).Across
CTs, patients in the experimental group reportedgreater reductions in symptom-
threshold events and symptom interferencewith functioning,40 severity ofmeno-
pausal symptoms and sexual dysfunction,22 frequency of constipation and
vomiting,25 incidenceof pain37 or fatigue,41 debilitating symptoms,18 anddistress
associated with symptoms/problems32,41 compared with those in the control
group, irrespective of cancer type or stage.
Quality of life. Survivors of breast cancer,22 patients with nonlocalized
breast cancer or colorectal cancer,23 and groups of patients withmixed cancer
diagnoses at an advanced stage21,31,42 or at various clinical stages24,28 had no
significant postintervention effects in nine CTs (Table 2; Appendix Table A3).
In terms of overall QoL, ES ranged from0.04 to 0.59, butweremainly small in
magnitude. Nevertheless, rates of diseased QoL were reduced in women with
breast cancer6months after surgery in the experimental groupcomparedwith
the control group (d 0.35).26 Among patients with lung cancer, QoL scores
deteriorated in the experimental groupmore than in the standard-care group
over the 16weeks of observation.29 Velikova et al38 reported improvements in
patient QoL scores at treatment initiation that were influenced by whether
QoL was actually discussed during consultations.38
Psychological symptoms. Results were generally unsupportive of signif-
icant postintervention effects on anxiety and/or depression regardless of
whether direct real-time18,23 or indirect20 patient feedbackwasmade available
to HPs. This was evident despite overall reductions in psychological distress
over time.27 Similarly,McLachlan et al28 found no overall intervention effects
on depression scores, but the subgroup of patients classified as moderately or
severely depressed benefitted more from the intervention. Where significant
improvements in anxiety or depression were reported,42 these were small-to-
moderate in magnitude (d 0.15 to 0.42) and not universal across all assess-
ment PROMs.
Supportive care needs. Five CTs provided generally unclear evidence;
despite some small-to-moderateES (d0.16 to 0.58) across domains of need,
thesewerenot always in favorof the experimental group(AppendixTableA3).
The PROM intervention was no better than usual care in tackling needs of
patients in two trials.18,23 We found statistically significant between-group
differences in 13 of 19 categories of perceived need32 and sexual health con-
cerns (d  0.49)22 in favor of the experimental group among patients with
hematologic malignancies32 and breast cancer,22 respectively. In a non-RCT,
patients receiving routine psychological screening reportedmore psychologi-
cal, information, and physical/daily living needs, but not sexuality needs, at 6
months postbaseline compared with the unscreened cohort.36
Processes of Care
Medical decisions made/advice given/changes in treatment/referrals made.
Despite being the outcomes most frequently investigated (Table 3), evidence
Records identified through database 
   searching
      Medline/EMBASE
      CINAHL, PsycINFO, PBSC
(n = 1,611)
(n = 3,386)
Additional records identified through 
   other sources




on basis of title/abstract
(n = 4,967)
Full-text articles assessed 
for eligibility 
(n = 49)









   PROMs not the intervention
   No active treatment
   Children with cancer
   No controlled trial
   No results reported
   Compared intervention 








Fig 1. Diagram of the study selection
process according to Preferred Report-
ing Items for Systematic Reviews and
Meta-Analyses guidelines.12,43 CINAHL,
Cumulative Index to Nursing and Allied
Health Literature; PBSC, Psychology and
Behavioral Sciences Collection; PROMs,
patient-reported outcome measures.
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of intervention effects on actions taken as a result of PROM feedback becom-
ing available to clinicians remains generally ambiguous (Appendix Table A4).
No significant intervention effects were reported in the number of patients
referred to psychosocial care19,20,36 or in clinical actions taken.21,24,31 Al-
though at 3 months after the intervention women with breast cancer in the
experimental groupwere offered counseling andpsychotherapy servicesmore
often, at 6 months this difference disappeared.26 When PROMs were used to
increase physician awareness of patients’ levels of pain, a significant change
(d  0.41) in analgesic prescription patterns was found to favor the experi-
mental group.37 During treatment for chest malignancies, significantly more
patients in theexperimental groupreceiveddiagnosticandtherapeutic services
for emotional and social concerns,30 but numbers of QoL-related actions
taken per patient were similar across study groups.34
Patient satisfaction with care and/or communication with team. Regard-
less of study condition, patient remarks on satisfaction with care and/or com-
munication with HPs were generally positive.19,21,24,28,29,31,34,39,40 Though
eight CTs19,24,28,29,31,34,40 failed to show significant intervention effects (Ap-
pendix Table A4). In the studies in which postintervention gains were re-
ported, the positive effects referred to greater satisfaction with emotional
support in the palliative chemotherapy context,21 greater satisfaction with
patients receiving follow-up from oncology nurses rather than general practi-
tioners (though differences from usual care were not examined),23 and en-
hanced communication with physicians in the outpatient setting compared
with standard care.39
Patient outcomes discussed during consultation. Regardless of patients’
cancer type, significant postintervention increases over time in the frequency
of discussions pertinent to patient outcomes during consultations were re-
corded.35,38 The odds of such outcomes being discussed seemed to depend on
whether these were reported at a level indicating a problem.17 Though emo-
tional problems tend to be discussed more often during consultations in the
experimental group,19 social and sexual functioning issues may be those on
which the intervention proves most effective.17 Still, the overall patient-
physician communicationmaynot significantly improve.19 In the lung cancer
population, significantly more symptoms were discussed and addressed dur-
ing consultations,34 but intervention effects on QoL discussions fell short of
significance. Much greater intervention effects were reported in the context of
palliative chemotherapy (Appendix Table A4),21 regarding overall communica-
tion about dyspnea (d  0.40 to 0.77)21,24; social functioning (d  0.49) and
fatigue (d  0.38)21; and sleep problems (d  0.66), constipation (d  0.40),
diarrhea (d 0.67), and cognitive functioning (d 0.66).24
HP acceptability/evaluation of intervention. Where addressed, interven-
tion acceptability was moderate to high across all CTs (Table 2), with rates of
perceivedusefulness ranging from less than50%to68%.HPs felt obtaining an
overall assessment of the patient was more helpful21,38,39 to identify issues of
concern17,19,21,38 and to guide discussions with patients17-19,24 rather than in
communicating with patients17,19 and in managing and enhancing the care
provided.18,38 Yet, in two similarCTs, all physicians21 andnurses24 agreed that
the intervention facilitated patient-clinician communication. The ability of
HPs to identify psychosocial concerns19,21 and address difficult subjects such
as sexuality issues24 was also enhanced. Although actual changes in HP com-
munication styles may not be seen even following the intervention,19 physi-
cians21,39 and nurses24 seemwilling to continue using the PROMsummary in
everyday practice. Nurses significantly more frequently found PROM
Table 3. Classification of Study Outcomes According to the Three Prespecified Outcome Categories (n  24)











7 29.2 Patient actual use of the intervention
PROM25,29
2 8.3 Health services use/
self-referrals20,22,42
3 12.5
QoL21-24,26,28,29,31,38,42 10 41.7 Duration of contacts with
HPs17-19,27,28,30,38
7 29.2 Contact with HPs27,30 2 8.3
Psychological
symptoms18,20,23,27,28,42





5 20.8 Patient outcomes discussed during
consultation17,19,21,24,29,30,34,35,38
8 33.3
Overall distress20,31,33 3 12.5 HP acceptability/evaluation of
intervention17-19,21,24,38,39
6 25.0




Working hours27 1 4.2 Patient outcomes addressed in
patient records32,34
2 8.3





Social activity27 1 4.2 HP use of PROM information38,39 1 4.2
Physical activity27 1 4.2 HP satisfaction with encounter with
the patient21
1 4.2












Timing of referrals19,36 2 8.3
Abbreviations: HP, health professional; PROM, patient-reported outcome measure; QoL, quality of life.
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interventions beneficial17 and felt that use of relevant information resulted in
more efficient use of their time.24
Patient satisfaction with intervention. Overall satisfactionwith interven-
tion was evident for at least 80% of patients.40,42 The PROM interventions
were seen as easy to use40 and a useful way for patients to describe their
situation39 and communicate important information to HPs.19 Patients ex-
pressed their willingness to continue using it in routine care.39,40 However, in
theKornblith et al42CT,percentagesofpatients rating thePROMintervention
asveryorextremelyhelpful incopingwithan importantproblemwerenotably
low and favored the control rather than the experimental group (37% v 14%;
d 0.69).More than 83%of patients regarded the PROMcontent important
for them and its use necessary for all patients receiving treatment.19,36 More-
over, almost all patients (93%) appreciated having been asked about their
emotionalwell-beingduring treatment.36 In thepalliative care setting,patients
agreed that the summary profile enhanced their physician’s or nurse’s aware-
ness of their health problems (79% to 89%), and that it would be useful as a
standard part of their consultations (87% to 99%).21,24
HP awareness of patient outcomes. In the context of palliative chemo-
therapy, no intervention effects were reported on the magnitude of patient-
physicianagreement aboutpatients’ physical, emotional, and socialwell-being
and daily activities (d 0.09 to 0.50; Appendix Table A4).21 The only excep-
tionwas greater agreement in ratings of social functioning in the experimental
group, but this applied only to the subgroup of patients who reported
moderate-to-severe problems.21 Oncology nurses’ awareness of daily activi-
ties, pain, and QoL was significantly higher in the experimental group during
the fourth patient visit.24 Positive intervention effects were reported in patient
care documentation in themedical records of patients being treated for hema-
tologic malignancies32 and in the number of QoL issues charted in records of
patients with lung cancer.34
Timing of referrals. One RCT revealed that PROM feedback resulted in
significantly earlier postconsultation referral of patients in the experimental
versus the control group by an average of threeweeks.19 In a sequential cohort
trial of patient-distress screening, average time to referral in the unscreened
cohortwas 14days comparedwith a considerably earlier referral of only 5days
in the screened cohort.36
Health Services Outcomes
Only fiveCTs explored the effects of the routine use of PROMsonHSOs
(Table 3; Appendix Table A5), namely, numbers of patients making use of
health services20,22,42 and frequency of contacts with health professionals.27,30
Ganz et al22 reportedonlyminimal use of services after referral to psychosocial
care in women with breast cancer; whereas prevalence of cases in which
patients sought professional help was similar irrespective of study group
amongnewlydiagnosedpatientswith lungcancer andbreast cancer.20Among
patients with advanced breast, colorectal, or prostate cancer, use of mental
health services at 6 months after intervention was equally minimal regardless
of study condition (P .34).42 In terms of frequency of patient-HP contacts,
positive intervention effects were found among women with breast cancer27
but not among patients with chest malignancies.30
DISCUSSION
We found only tentative evidence regarding the effectiveness of
PROM interventions to improve the quality of care provided to pa-
tients receiving active anticancer treatments.Weused strict systematic
methods during identification12 and risk-of-bias appraisal13 of all
trials included here. We included 24 CTs, which investigated a wide
range of outcomes, thus producing a disparate set of data and indicat-
ing lack of consensus around the role of PROMs and the range of
outcome measures in clinical practice. Evidence suggests that, irre-
spectiveof the contextof chronic illness, the impactofPROMsonPOs
isweak.9,44Where possible, we calculatedES in an attempt to quantify
the magnitude of these effects, and our findings indicate inconsisten-
cies in the overall significance (statistical or clinical) and low-to-
moderate intervention effectiveness. Importantly, efficacy of the CTs
reviewed seems low, confirming findings from previous reviews.5,9,44
Contrary to the limited evaluation ofHSOs, PoCswere themost
frequently investigated outcomes in our sample of trials. Mixed find-
ings emerged regarding medical decisions made or actions taken by
HPs as a result of the availability of PROM data. Changes in HP
practices fell short of significance and, where such changes were doc-
umented,30,37 the associated ES were still small. It is unclear whether
limited referral options, additional subjective HP assessments, or
other health carerelated factors influenced the use of PROMs in
practice. Patient satisfaction with care did not improve significantly,
possibly owing to the presence of ceiling effects.Moreover, achievable
improvements inpatient communicationwithHPs, especially regard-
ing emotional health issues, were documented, but ES were quite
small. Somewhat greater ES can be proposedwith regard to the actual
discussion of POs during consultations, particularly physical symp-
toms, but not necessarily around supportive care needs.19
Fewer than 30% of the CTs addressed the important question of
whether the use of PROM interventions appeals to patients and HPs.
ThoughHPsmay view PROMs as useful toward amore comprehen-
siveor systematic assessment, communication isnotalwaysenhanced.
In addition, there is still limited (albeit positive) evidence about
whether HPs wish PROMs to become routine practice. Whether pa-
tients can complywith the systematic use ofPROMsduring treatment
and encounters with the clinical team is equally unclear. Despite
limited evidence, including electronic systems to enhance data collec-
tion andmanagement, as well as use of clinical algorithms to support
clinicians in the management of identified areas for intervention,
might potentially increase adherence to and acceptability of PROM-
enhanced clinical assessments.
Current data also suggest that patient physical symptoms and
distress may be more amenable to improvement after PROM inter-
ventions than QoL, supportive care needs, or psychological symp-
toms.Evenwith the exceptionof the few studies that examined theuse
of health services by patients or contacts with HPs, important aspects
of an intervention’s applicability, such as patient safety or cost-
effectiveness andcost-efficiency, areyet tobe includedaspotential end
points to encourage policymakers to consider making changes in the
way cancer care is provided. Despite this lack of evidence, theDepart-
ment of Health in England is aiming to extend the use of PROMs in a
wider range of conditions in that country’s National Health Service,45
which would include cancer care.
Finally, measurement bias interfering with the effects of PROM
interventions documented in this review should also be considered.
Arguably, not all tools used in the delivery of interventions were
originally developed as PROMs, which might have affected the reli-
ability of reported outcomes and their subsequent interpretation. In
addition, the psychometric robustness of the PROMs used to deliver
and/or evaluate intervention effects is questionable and might have
interfered with its ability to capture the actual magnitude of such
effects. Similar comments canbemade regarding sources of bias, such
as absence of randomization or uncertainty about whether clinicians
did use information generated by PROMs during consultations,
whichmay have further affected the trials’ internal and external valid-
ity and adversely affected credibility of available evidence.
Our search strategy was purposefully inclusive, with an aim to
include all relevant literature. However, it was limited to the most
common bibliographic databases, as well as to peer-reviewed articles
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and reports published in the English language only. In addition, the
gray literaturewasnot searched.Owing to thevastheterogeneity in the
studies included, a meta-analytic synthesis was not feasible. Unavail-
ability of data also prevented us from calculating ES for some of the
included studies. However, such cases were equally distributed across
statistically significant andnonsignificantfindings or across thediffer-
ent outcome categories; hence, we are confident that the associated
reporting bias has not greatly affected our conclusions.
More research is necessary on the effects of PROM interventions
on health outcomes across different types of cancers and treatment
modalities. The use of PROMs in clinical practice seems to be most
effective in increasing patient satisfaction with communication about
emotional concerns. Discussion of POs during consultations may
increase and, in some studies, is associated with improved symptom
control, increased supportive care measures, and patient satisfaction.
Additional patient-related outcomes could be usefully addressed in
future trials, including perceived self-care self-efficacy, social activity,
work limitations, or survival. Patients andHPs arewilling to engage in
the routine use of PROMsduring anticancer treatment.However, it is
paramount that PROM intervention implementation is effective and
incorporates strategies that increase patient adherence to the actual
use of PROMs and HP engagement in the active incorporation of
PROM feedback during encounters with patients.44 Consensus is also
required on the standardization of PROMs to be used in future trials.
Finally, dedicated research is required to support the cost-effective use
of PROMs in clinical practice regarding patient safety, clinician bur-
den, and health-services usage. This is an important area of consider-
ation, particularly in times of increasing demands on health care.
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Appendix
Table A1. Electronic Databases Searched and Search Terms Used
Electronic Databases Search Terms Used
Medline (1946 to May 2012) 1. exp controlled clinical trial/
EMBASE (1974 to May 2012) 2. exp randomized controlled trial/
CINAHL (inception to May 2012) 3. 1 OR 2
PsycINFO (inception to May 2012) 4. exp neoplasms/OR cancer.mp. OR neoplasm.mp. OR carcinoma.mp. OR oncol.mp. OR
malignan.mp. OR tumor.mp. OR tumour.mp. OR leukemia.mp. OR leukaemia.mp. OR
sarcoma.mp. OR lymphoma.mp. OR melanoma.mp. OR blastoma.mp.
PBSC (inception to May 2012) 5. 3 AND 4
6. (patient reported outcomes OR patient reported outcome OR patient based outcome OR patient
reported outcome measure$).mp.
7. inventory.ti. OR inventory.ab.
8. instrument.ti. OR instrument.ab.
9. measure.ti.
10. self report.ti. OR self report.ab.
11. 7 OR 8 OR 9 OR 10
12. 6 OR 11
13. 5 AND 12
14. Remove duplicates from 13
15. Limit 14 to abstracts
16. Limit 15 to English language
NOTE: Search strategy as conducted in Ovid Medline.
Abbreviations: ab, abstract; CINAHL, Cumulative Index to Nursing and Allied Health Literature; exp, term explosion; mp, free text search for a term; PBSC,
Psychology and Behavioral Sciences Collection; ti, title.
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Table A2. Intervention and Outcome Assessment PROMs Used in the 24 Studies Reviewed (n  26 articles)
Author and Publication
Year Intervention PROM(s) Outcome Assessment PROM(s)
Same Intervention/Outcome
PROM(s)





Author-developed questionnaire regarding clinic visit
duration; clinician evaluation of the intervention




Braeken et al,19 2011 SIPP Medical records
Intervention evaluation inventories
No
Carlson et al,20 2010 DT and problem list DT and problem list Yes
PSSCAN part C PSSCAN part C
Cleeland et al,40 2011 MDASI MDASI Yes
Author-developed form for patient evaluation of the
intervention





Patient Satisfaction Questionnaire C
Physician satisfaction with communication
SF-36
Patient/physician evaluation of the intervention
survey
Ganz et al,22 2000 Daily diary symptom cards Daily diary symptom cards Yes, plus additional PROMs
CARES (sexual summary scale) CARES (sexual summary scale)
RAND Vitality Scale
Girgis et al,23 2009 HADS HADS Yes, plus additional PROMs
EORTC QLQ-C30 EORTC QLQ-C30
SCNS-SF34 SCNS-SF34
NA-ACP NA-ACP
Patient perceptions of improved communication
Hilarius et al,24 2008 EORTC QLC-C30 Self-report communication questionnaire No
EORTC LC13 COOP
EORTC BR23 WONCA




Patient/nurse evaluation of the intervention
questionnaire
Hoekstra et al,25 2006 The Symptom Monitor The Symptom Monitor Yes
Kearney et al,41 2009 Author-developed symptom
questionnaire integrating the
CTCAE grading system and the
CSAS (electronic version)
Author-developed symptom questionnaire





EORTC QLC-C30 EORTC QLC-C30 Yes, plus additional PROMs
EORTC BR23 EORTC BR23
Medical records
Kornblith et al,42 2006 HADS HADS Yes, plus additional PROMs
EORTC QLQ-C30 EORTC QLQ-C30
MOS-SSS MOS-SSS
GDS-SF
OARSQ, physical health subscale
Utilization of mental health and psychosocial
services scale
GSRE
Patient satisfaction with research program
(continued on following page)
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Table A2. Intervention and Outcome Assessment PROMs Used in the 24 Studies Reviewed (n  26 articles) (continued)
Author and Publication
Year Intervention PROM(s) Outcome Assessment PROM(s)
Same Intervention/Outcome
PROM(s)





Perceptions of health and worries about health
Number of visits to HP
Medical records
McLachlan et al,28 2001 CNQ-SF CNQ-SF Yes, plus additional PROMs
EORTC QLQ-C30 EORTC QLQ-C30
BDI-SF BDI-SF
Patient satisfaction survey




Patient satisfaction with care survey
Nicklasson et al,30 2013 EORTC QLQ-C30 Audio-recorded consultations No






Clinical treatment changes survey
Ruland et al,32 2010 Choice ITPA Choice ITPA Yes, plus additional PROMs
Chart audit
Sarna,33 1998 SDS SDS Yes
Taenzer et al,34 2000 EORTC QLQ-C30 PDIS No
Exit interview
Medical record audit
Takeuchi et al,35 2011 EORTC QLQ-C30 Audio-recorded consultations No
HADS
Thewes et al,36 2009 DT Medical records No
SPHERE-Short SCNS-SF34
Satisfaction with intervention, Likert scales
Trowbridge et al,37
1997
Pain inventories Pain inventories Yes, plus additional PROMs
PMI
Chart audit
Velikova et al,38 2004 EORTC QLQ-C30 Audio-recorded consultations No
HADS FACT-G
Physician use of QoL information checklist
Velikova et al,39 2010 EORTC QLQ-C30 MCQ No
HADS Satisfaction with care, single-item scales
Intervention evaluation questionnaires
Abbreviations: BDI, Beck Depression Inventory; Brief POMS-17, Brief Profile of Mood States-17; BR-23, Breast Cancer 23 Module; CARES, Cancer Rehabilitation
Evaluation System; CNQ-SF, Cancer Needs Questionnaire–Short Form; COOP, Dartmouth Primary Care Cooperative Information Functional Health Assessment;
CR-38, Colorectal Cancer 38 Module; CSAS, Chemotherapy Symptom Assessment Scale; CTCAE, Common Toxicity Criteria Adverse Events; DT, Distress
Thermometer; EORTC-LC13, European Organisation for Research and Treatment of Cancer–Lung Cancer Module 13; EORTC QLQ-C30, European Organisation for
Research and Treatment of Cancer–Core Quality of Life Questionnaire, version 3.0; FACT-G, Functional Assessment of Cancer Therapy–General; FACT-L/C/BCS,
Functional Assessment of Cancer Therapy–Lung/Colorectal/Breast Cancer Subscale; FLIC, Functional Living Index Cancer; GDS-SF, Geriatric Depression Scale–Short
Form; GHQ, General Health Questionnaire; GSRE, Geriatric Schedule of Recent Experience; HADS, Hospital Anxiety and Depression Scale; HP, health professional;
ITPA, interactive tailored patient assessments; LC-13, Lung Cancer 13 Module; LES, Life Experiences Survey; LWMAT, Lock-Wallace Marital Adjustment Test;
MCQ, Medical Care Questionnaire; MDASI, MD Anderson Symptom Inventory; MOS-SSS, Medical Outcomes Study–Social Support Survey; NA-ACP, Needs
Assessment for Advanced Cancer Patients; OARSQ-Physical Health, Older American Resources and Services Questionnaire–Physical Health; PDIS, Patient
Satisfaction Questionnaire; PHQ-9, Patient Health Questionnaire–9; PMI, Pain Management Index; PQLI, Palliative Care Quality of Life Index; PROM,
patient-reported outcome measure; PSI, Psychiatric Symptom Index; PSQ-III/II, Medical Outcomes Study–Patient Satisfaction Questionnaire III/II; PSSCAN Part C,
Psychological Screen for Cancer–Part C; QoL, quality of life; RAND, Research and Development; SCNS-SF31, Supportive Care Needs Survey–Short Form 31;
SCNS-SF34, Supportive Care Needs Survey–Short Form 34; SDS, Symptom Distress Scale; SF-36, Medical Outcomes Study 36-Item Short Form Health Survey;
SIPP, Screening Inventory of Psychosocial Problems; SPHERE-Short, Somatic and Psychological Health Report–Short form; SSS, Subject Significance Scale; TOI,
Trial Outcome Index; WONCA, World Organization Project of National Colleges and Academics.
If no specific PROM was used, method of assessment is reported instead.
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Table A3. Evaluation of PROM Intervention Effects on Patient Outcomes
Outcome ES (d) 95% CI† Effect Characterization‡
Menopausal symptom distress 1.18 1.68 to 0.6722 
Prevalence
Anxiety 0.07 0.41 to 0.2723 
Depression 0.15 0.73 to 0.4323 
Overall supportive care needs 0.20 0.46 to 0.0623 
0.5836 
Need for help
Psychological needs 0.16 0.73 to 0.4018 
0.5036 
Information needs 0.29 0.86 to 0.2818 
0.5336 
Patient care and support 0.47 1.05 to 0.1018 
Physical and daily living 0.34 0.91 to 0.2418 
0.4636 
Sexual functioning 0.49 0.96 to 0.0222 
QoL
Role functioning 0.04 0.26 to 0.1923 
0.12 0.40 to 0.1621 
Emotional/psychological functioning 0.18 0.41 to 0.0523 
0.1131 
0.20 0.48 to 0.0721 
0.10 0.25 to 0.4442 
Cognitive functioning 0.05 0.27 to 0.1823 
Social functioning 0.01 0.24 to 0.2223 
0.0431 
0.07 0.35 to 0.2121 
Physical functioning 0.16 0.39 to 0.0123 
0.1231 
0.04 0.32 to 0.2421 
0.20 0.55 to 0.1542 
Physical and functional well-being 0.41 0.95 to 0.1429 
Mental health 0.10 0.38 to 0.1821 
Vitality 0.08 0.38 to 0.5422 
0.08 0.36 to 0.2021 
Bodily pain 0.07 0.35 to 0.2121 
Nausea 0.1631 
Hardship owing to cancer 0.0531 
Overall QoL 0.05 0.28 to 0.1723 
0.1431 
0.59 1.16 to 0.0129 
0.35 0.70 to 0.00126 
0.04 0.38 to 0.3142 
Severity
Fatigue 0.37 0.77 to 0.0425 
0.25 0.63 to 0.1241 
Pain 0.04 0.36 to 0.4425 
Lack of appetite 0.04 0.44 to 0.3625 
Shortness of breath 0.05 0.35 to 0.4525 
Sore mouth/throat 0.32 0.05 to 0.6941 
Coughing 0.37 0.77 to 0.0325 
Sleeplessness 0.31 0.71 to 0.0925 
Hand-foot syndrome 0.42 0.05 to 0.7941 -
Nausea 0.44 0.84 to 0.0425 
0.18 0.55 to 0.2041 
Constipation 0.24 0.16 to 0.6425 
Diarrhea 0.0 0.40 to 0.4025 
0.06 0.32 to 0.4341 
Vomiting 0.33 0.07 to 0.7325 
0.01 0.36 to 0.3841 
Anxiety 0.09 0.65 to 0.4818 
0.0520 
0.30 0.65 to 0.0442 
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Table A3. Evaluation of PROM Intervention Effects on Patient Outcomes (continued)
Outcome ES (d) 95% CI† Effect Characterization‡
Depression 0.08 0.49 to 0.6418 
0.0120 
0.15 0.49 to 0.2042 
Psychological distress 0.09 0.34 to 0.1627 
0.42 0.76 to 0.0742 
Prevalence
Fatigue 0.07 0.62 to 0.4725 
0.29 0.60 to 0.0218 
0.2041 
Pain 0.33 0.78 to 0.1225 
Lack of appetite 0.29 0.74 to 0.1525 
0.19 0.55 to 0.1818 
Shortness of breath 0.06 0.50 to 0.3825 
Coughing 0.34 0.11 to 0.7925 
Sleeplessness 0.40 0.85 to 0.0425 
Nausea 0.10 0.57 to 0.3725 
0.06 0.79 to 0.6718 
0.1041 
Constipation 0.73 1.29 to 0.1725 
0.06 1.60 to 1.4918 
Diarrhea 0.32 0.90 to 0.2725 
0.88 2.10 to 0.3718 
0.0141 
Vomiting 0.98 1.83 to 0.1325 
0.0541 
Skin rash 0.06 1.60 to 1.4918 
Sore mouth 0.25 0.58 to 1.0818 
0.0641 
Metallic taste 0.06 1.17 to 1.0518 
Hot flashes 0.75 0.48 to 1.9818 
Hand-foot syndrome 0.2341 
Overall distress 0.1520 
Distress
Vomiting 0.05 0.32 to 0.4241 
Nausea 0.15 0.52 to 0.2241 
Diarrhea 0.0 0.37 to 0.3741 
Hand-foot syndrome 0.35 0.02 to 0.7241 
Sore mouth/throat 0.33 0.05 to 0.7041 
Fatigue 0.31 0.69 to 0.0641 
Overall 0.0231 
0.1620 
Health status 0.01 0.34 to 0.3327 
0.0 0.34 to 0.3442
Worry about health 0.10 0.39 to 0.2027 
Working during assessment 0.01 0.28 to 0.3027 
Hours worked per week 0.05 0.30 to 0.2027 
Household activities performed 0.08 0.33 to 0.1727 
Engagement in social activities 0.23 0.48 to 0.0227 
Engagement in leisure activities 0.14 0.11 to 0.3927 
Engagement in physical activities 0.02 0.27 to 0.2327 
Marital satisfaction 0.0 0.25 to 0.2527 
NOTE. Negative ES denote more favorable outcomes (eg, less severity or better scores) for the intervention group, and vice versa. ES were not calculated for
controlled trials that reported pre-intervention between-group differences in the outcome in question, or where no relevant data were available. Where data were
available, but no such baseline comparisons were performed/stated, baseline scores/percentages were compared using two-tailed independent sample t tests, thus
ensuring that postintervention scores were not a result of preintervention differences. When studies reported results at more than one time point, the final time
point was used, thus ensuring independence of data; hence, each study contributed no more than one ES for a specific outcome.14 For studies with more than one
experimental group, separate ES were calculated if different intervention PROMs were used; however, if the same intervention PROM was used, one ES was
calculated based on pooled experimental versus control effects. If a study indicated that the effect was nonsignificant but no statistics were provided, ES was
entered as zero.
Abbreviations: ES, effect sizes; PROM, patient-reported outcome measure; QoL, quality of life.
ES calculations were performed only in those studies for which enough data were available.
†Where no 95% CIs are reported, not enough data were available to calculate them.
‡Based on P values (P  .05) and direction;  favors the intervention group (P  .05);  favors the control group (P  .05);  represents P  .05.
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Table A4. Evaluation of PROM Intervention Effects on Processes of Care
Outcome ES (d) 95% CI† Effect Characterization‡
Action
Enrolled onto medical trial 0.15 0.53 to 0.2227 
Met with other survivors 0.14 0.41 to 0.1427 
Participated in patient-support group 0.02 0.47 to 0.4327 
Consulted treating oncologist 0.22 0.52 to 0.0924 
Consulted family physician 0.002 0.33 to 0.3227 
Consulted other physician 0.10 0.38 to 0.1827 
Had consultation for CAM therapies 0.18 0.54 to 0.1927 
Had psychiatric/psychological consultation 0.02 0.44 to 0.4027 
Sought help because of feeling depressed/sad 0.11 0.41 to 0.1927 
Had a confidant 0.27 0.67 to 0.1327 
Participated in relaxation activities 0.05 0.43 to 0.3227 
Made dietary changes 0.13 0.14 to 0.4127 
Discussed
Nausea/vomiting 0.06 0.26 to 0.1417 
0.22 0.08 to 0.5224 
0.0238 
0.07 0.41 to 0.2721 
Appetite 0.06 0.24 to 0.1317 
0.09 0.41 to 0.2224 
0.4038 
0.34 0.65 to 0.0330 
0.06 0.25 to 0.3721 
Insomnia/sleep problems 0.05 0.23 to 0.1317 
0.66 1.00 to 0.3224 
0.6438 
0.13 0.50 to 0.2421 
Pain 0.02 0.16 to 0.1917 
0.10 0.39 to 0.2024 
0.0138 
0.05 0.36 to 0.2530 
0.30 0.62 to 0.0321 
Fatigue 0.0 0.19 to 0.1917 
0.13 0.43 to 0.1724 
0.3438 
0.06 0.36 to 0.2530 
0.38 0.69 to 0.0721 
Bowel pattern 0.14 0.05 to 0.3317 
Constipation 0.40 0.72 to 0.0824 
Diarrhea 0.67 1.04 to 0.3024 
Concentration 0.29 0.64 to 0.0717 
Appearance 0.19 0.07 to 0.4517 
Impact on sex 0.58 0.99 to 0.1717 
Breathing/dyspnea 0.01 0.18 to 0.1917 
0.77 1.22 to 0.3324 
0.1538 
0.18 0.48 to 0.1330 
0.40 0.82 to 0.0221 
Outlook 0.05 0.24 to 0.1517 
Cough 0.05 0.24 to 0.1417 
Fever/chills 0.03 0.21 to 0.1517 
Depression 0.12 0.36 to 0.1317 
Suicidal ideation 0.26 0.89 to 0.3617 
Symptoms of illness 0.07 0.38 to 0.2330 
0.02 0.52 to 0.5629 
Physical functioning 0.03 0.15 to 0.2117 
0.26 0.10 to 0.6324 
0.2138 
0.18 0.48 to 0.1330 
0.98 1.31 to 0.6421 
0.05 0.26 to 0.1719 
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Table A4. Evaluation of PROM Intervention Effects on Processes of Care (continued)
Outcome ES (d) 95% CI† Effect Characterization‡
Emotional functioning 0.11 0.28 to 0.0717 
0.05 0.28 to 0.3724 
0.2438 
0.44 0.75 to 0.1330 
0.17 0.48 to 0.1421 
0.26 0.29 to 0.8129 
0.19 0.38 to 0.0119 
Social functioning 0.14 0.37 to 0.0817 
0.18 0.59 to 0.2324 
0.1938 
0.21 0.51 to 0.1030 
0.05 0.49 to 0.6229 
0.49 0.93 to 0.0421 
0.16 0.38 to 0.0619 
Cognitive functioning 0.08 0.35 to 0.1817 
0.66 1.19 to 0.1224 
0.3338 
0.0 0.31 to 0.3130 
0.36 0.97 to 0.2521 
Daily functioning 0.14 0.22 to 0.5024 
0.38 0.19 to 0.9429 
Role functioning 0.01 0.18 to 0.2017 
0.1538 
0.33 0.23 to 0.9029 
0.70 0.37 to 1.0321 -
Sexual problems 0.06 0.16 to 0.2819 
Impact on family relationships 0.30 0.25 to 0.8529 
Existential issues 0.0 0.31 to 0.3130 
Financial issues 0.10 0.20 to 0.4130 
0.02 0.53 to 0.5829 
Medical/technical issues/effects of treatment 0.27 0.04 to 0.5730 
0.23 0.33 to 0.7829 
Overall condition 0.37 0.20 to 0.9529 
Global QoL 0.01 0.24 to 0.2117 
0.45 0.76 to 0.1430 
0.10 0.21 to 0.4130 
No. of concerns/symptoms discussed during consultations 1.09 1.67 to 0.5234 
0.4138 
0.38 0.66 to 0.1021 
No. of concerns/issues charted on patient records by nurses 0.54 0.81 to 0.2724 
0.6832 
No. of concerns/issues charted on patient records by physicians 0.3332 
No. of concerns/issues charted on patient records by health
professionals, mixed sample 0.49 1.04 to 0.0534 
Average duration of contact 0.18 0.07 to 0.4327 
0.08 0.24 to 0.0917 
0.12 0.13 to 0.3728 
0.0938 
0.03 0.27 to 0.3330 
0.09 0.19 to 0.3721 
Satisfaction with nursing care 0.56 1.40 to 0.2828 
Satisfaction with medical care 0.16 1.16 to 0.8428 
Satisfaction with information received 0.50 1.12 to 0.1228 
0.18 0.36 to 0.7234 
0.03 0.53 to 0.6029 
Satisfaction with support/rapport/communication 0.0 0.54 to 0.5434 
0.0731 
0.04 0.61 to 0.5329 
0.37 0.65 to 0.0921 
0.13 0.05 to 0.3119 
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Table A4. Evaluation of PROM Intervention Effects on Processes of Care (continued)
Outcome ES (d) 95% CI† Effect Characterization‡
Satisfaction with help received about important problems 0.69 0.20 to 1.1742 -
Satisfaction with involvement in decision-making 0.14 0.42 to 0.7129 
Satisfaction with HPs addressing patient needs 0.35 0.90 to 0.1934 
0.13 0.44 to 0.6929 
Overall satisfaction with care 0.39 1.92 to 1.1528 
0.0839 
0.3331 
0.13 0.44 to 0.6929 
Overall satisfaction with intervention 0.52 1.03 to 0.0142 
Intervention acceptability, comfortable with using the
system 0.49 0.94 to 0.0440 
Intervention acceptability, system easy to use 0.59 0.14 to 1.0540 
HP satisfaction with clinical encounter 0.021 
HP action
No. of actions taken/medical decisions made per patient 0.40 0.94 to 0.1534 
0.1638 
0.0231 
0.32 0.62 to 0.0230 
Referred to psychosocial care or other provider 0.08 0.27 to 0.4219 
0.31 0.87 to 0.2636 
0.01 0.31 to 0.2824 
0.11 0.22 to 0.4326 
0.3220 
0.04 0.18 to 0.2619 
Prescription of medication 0.26 0.07 to 0.6024 
0.41 0.72 to 0.0937 
Ordering tests 0.11 0.45 to 0.2224 
Changing/stopping chemotherapy 0.05 0.38 to 0.2724 
Offering counseling on managing health problems 0.26 0.65 to 0.1421 
HP awareness of patient outcomes
Physical 0.13 0.40 to 0.1424 
0.21 0.69 to 0.2721 
Feelings 0.16 0.43 to 0.1124 
0.13 0.66 to 0.3921 
Daily activities 0.28 0.55 to 0.0124 
0.09 0.41 to 0.5921 
Social activities 0.09 0.35 to 0.1824 
0.50 1.05 to 0.0521 
Overall health 0.20 0.47 to 0.0724 
0.19 0.27 to 0.6421 
Pain 0.54 0.82 to 0.2724 
0.20 0.34 to 0.7421 
Fatigue 0.15 0.41 to 0.1224 
0.18 0.58 to 0.2321 
QoL 0.27 0.54 to 0.024 
Prevalence of patients undertreated for pain 0.07 0.33 to 0.1837 
NOTE. Negative ES denote more favorable outcomes (ie, more frequent discussion or better communication) for the intervention group and vice versa. ES were
not calculated for controlled trials that reported preintervention between-group differences in the outcome in question or where no relevant data were available.
Where data were available but no such baseline comparisons were performed/stated, baseline scores/percentages were compared using two-tailed independent
sample t tests, thus ensuring that postintervention scores were not because of preintervention differences. When studies reported results at more than one time
point, the final time point was used, thus ensuring independence of data. Hence, each study contributed no more than one ES for a specific outcome.14 For studies
with more than one experimental group, separate ES were calculated if different intervention PROMs were used; however, if the same intervention PROM was
used, one ES was calculated based on pooled experimental versus control effects. If a study indicated that the effect was not significant but no statistics were
provided, ES was entered as zero.
Abbreviations: CAM, complementary/alternative medicine; ES, effect sizes; HP, health professional; PROM, patient-reported outcome measure; QoL, quality of life.
ES calculations were performed only in those studies for which enough data were available.
†Where no 95% CIs are reported, not enough data were available to calculate them.
‡Based on P value (P  .05) and direction;  favors the intervention group (P  .05);  favors the control group (P  .05);  represents P  .05.
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Table A5. Evaluation of PROM Intervention Effects on Health Service Outcomes
Outcome ES (d) 95% CI Effect Characterization†
Patient use of psychological referrals 0.10 1.02 to 0.8222 
Self-referrals 0.20 0.44 to 0.0420 
Patient contacts with health professional 0.85 1.10 to 0.5927 
0.15 0.45 to 0.1530 
Patient use of mental health services 0.18 0.45 to 0.8242 
NOTE. Negative effect sizes denote more favorable outcomes (eg, more frequent use of service or more contacts) for the intervention group and vice versa. ES
were not calculated for controlled trials that reported preintervention between-group differences in the outcome in question or where no relevant data were available.
Where data were available but no such baseline comparisons were performed or stated, baseline scores/percentages were compared using two-tailed independent
sample t tests, thus ensuring that postintervention scores were not because of preintervention differences. When studies reported results at more than one time
point, the final time point was used, thus ensuring independence of data. Hence, each study contributed no more than one ES for a specific outcome.14 For studies
with more than one experimental group, separate ES were calculated if different intervention PROMs were used; however, if the same intervention PROM was
used, one ES was calculated based on pooled experimental versus control effects. If a study indicated that the effect was nonsignificant but no statistics were
provided, ES was entered as zero.
Abbreviations: ES, effect size; PROM, patient-reported outcome measure.
ES calculations were performed only in those studies for which enough data were available.
†Based on P value (P  .05) and direction;  (P  .05 favors intervention group);  P  .05 favors control group);  (P  .05).
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